RARE Projected Dividend Yield
Ultragenyx Pharmaceutical Inc ( NASDAQ : RARE )Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultrarare genetic diseases. Their therapies and pipeline include biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Approved products are Crysvita for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii for mucopolysaccharidosis VII (MPSVII), Dojolvi for long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza for homozygous familial hypercholesterolemia (HoFH). Clinical candidates include DTX401 for glycogen storage disease type Ia, DTX301, and UX701. 21 YEAR PERFORMANCE RESULTS |
RARE Dividend History Detail RARE Dividend News RARE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |